{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:25:37Z","timestamp":1767918337770,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[1999,8]]},"DOI":"10.1016\/s1367-5931(99)80067-2","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T13:27:54Z","timestamp":1027603674000},"page":"459-465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":148,"title":["The development and therapeutic potential of protein kinase inhibitors"],"prefix":"10.1016","volume":"3","author":[{"given":"Philip","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S1367-5931(99)80067-2_reference0005","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","article-title":"Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2141.1998.00564.x","article-title":"Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors","volume":"100","author":"Jonuleit","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/S1367-5931(99)80067-2_bib3","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jnci\/91.2.163","article-title":"In vivo eradication of human BCR\/ABL-positive leukaemia cells with an ABL kinase inhibitor","volume":"91","author":"Le Coutre","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S1367-5931(99)80067-2_bib5","doi-asserted-by":"crossref","first-page":"21682","DOI":"10.1074\/jbc.273.34.21682","article-title":"Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans","volume":"34","author":"Ruckemann","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80067-2_bib6","series-title":"Abstract at the American Association for Cancer Research","article-title":"SU 101, a potent inhibitor of PDGF-mediated signaling, inhibits growth of a wide variety of tumor types in vivo","author":"Shawver","year":"1996"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0035","first-page":"348","article-title":"EGF receptor tyrosine kinase inhibitors as anti-cancer agents: pre-clinical and early clinical profile of ZD 1839","volume":"3","author":"Woodburn","year":"1998","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/S1367-5931(99)80067-2_bib8","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/S1367-5931(99)80067-2_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/379645a0","article-title":"Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor","volume":"379","author":"Meydan","year":"1996","journal-title":"Nature"},{"key":"10.1016\/S1367-5931(99)80067-2_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0055","first-page":"99","article-title":"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumour vacularisation and growth of multiple tumour types","volume":"59","author":"Fong","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/S1367-5931(99)80067-2_bib12","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1093\/emboj\/17.20.5896","article-title":"Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain","volume":"17","author":"Mohammadi","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/S1367-5931(99)80067-2_bib13","first-page":"7686","article-title":"A synthetic inhibitor of the mitogen-activated protein kinase cascade","volume":"92","author":"Dudley","year":"1995"},{"key":"10.1016\/S1367-5931(99)80067-2_bib14","doi-asserted-by":"crossref","first-page":"27489","DOI":"10.1074\/jbc.270.46.27489","article-title":"PD 98059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo","volume":"270","author":"Alessi","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0075","doi-asserted-by":"crossref","first-page":"18623","DOI":"10.1074\/jbc.273.29.18623","article-title":"Identification of a novel inhibitor of mitogen-activated protein kinase kinase","volume":"273","author":"Favata","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0080","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.4049\/jimmunol.160.9.4175","article-title":"Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy","volume":"160","author":"DeSilva","year":"1999","journal-title":"J Immun"},{"key":"10.1016\/S1367-5931(99)80067-2_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","article-title":"Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5","volume":"243","author":"Meijer","year":"1997","journal-title":"Eur J Biochem"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0090","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.281.5376.533","article-title":"Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors","volume":"281","author":"Gray","year":"1998","journal-title":"Science"},{"key":"10.1016\/S1367-5931(99)80067-2_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0959-437X(98)80062-2","article-title":"Mechanism of action and function of protein kinase B","volume":"8","author":"Alessi","year":"1998","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/S1367-5931(99)80067-2_bib20","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/40187","article-title":"Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension","volume":"389","author":"Uehata","year":"1997","journal-title":"Nature"},{"key":"10.1016\/S1367-5931(99)80067-2_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-5793(98)01455-0","article-title":"The effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-, GTP gamma S-, and phorbol ester-induced Ca2+-sensitization of smooth muscle","volume":"440","author":"Fu","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/S1367-5931(99)80067-2_bib22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.273.5272.245","article-title":"Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase)","volume":"273","author":"Kimura","year":"1996","journal-title":"Science"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0115","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0960-9822(99)80067-0","article-title":"Transformation mediated by RhoA requires activity of ROCK kinases","volume":"9","author":"Sahai","year":"1999","journal-title":"Curr Biol"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/5587","article-title":"An essential part for Rho-associated kinase in the transcellular invasion of tumor cells","volume":"5","author":"Itoh","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0014-5793(99)00098-8","article-title":"Rho-kinase in human neutrophils: a role in signalling for myosin light chain phosphorylation and cell migration","volume":"445","author":"Niggli","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0130","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1091\/mbc.9.8.2287","article-title":"Na-H exchange acts downstram of RhoA to regulate integrin-induced cell adhesion and spreading","volume":"9","author":"Tominaga","year":"1998","journal-title":"Mol Biol Cell"},{"key":"10.1016\/S1367-5931(99)80067-2_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0968-0896(96)00212-X","article-title":"Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase","volume":"5","author":"Gallagher","year":"1997","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/S1367-5931(99)80067-2_bib28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/372739a0","article-title":"A protein kinase involved in the regulation of inflammatory cytokine biosynthesis","volume":"372","author":"Lee","year":"1994","journal-title":"Nature"},{"key":"10.1016\/S1367-5931(99)80067-2_bib29","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0022-3565(25)21307-6","article-title":"Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein\/p38 kinase in animal models of arthritis, bone resorption, endotoxin shock and immune function","volume":"279","author":"Badger","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S1367-5931(99)80067-2_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0014-5793(95)00357-F","article-title":"SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin 1","volume":"364","author":"Cuenda","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/S1367-5931(99)80067-2_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0962-8924(97)01105-7","article-title":"The search for physiological substrates of MAP and SAP kinases in mammalian cells","volume":"7","author":"Cohen","year":"1997","journal-title":"Trends Cell Biol"},{"key":"10.1016\/S1367-5931(99)80067-2_bib32","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0955-0674(97)80078-6","article-title":"TOR signalling and the control of cell growth","volume":"9","author":"Thomas","year":"1997","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/S1367-5931(99)80067-2_bib33","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1126\/science.276.5314.955","article-title":"Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors","volume":"276","author":"Mohammadi","year":"1997","journal-title":"Science"},{"key":"10.1016\/S1367-5931(99)80067-2_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nsb0497-311","article-title":"A highly specific inhibitor of p38 MAP kinase binds in the ATP pocket","volume":"4","author":"Tong","year":"1997","journal-title":"Nat Struct Biol"},{"key":"10.1016\/S1367-5931(99)80067-2_bib35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1074-5521(97)90194-0","article-title":"The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase","volume":"4","author":"Wilson","year":"1997","journal-title":"Chem Biol"},{"key":"10.1016\/S1367-5931(99)80067-2_bib36","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1432-1033.1997.0518a.x","article-title":"Inhibition of cyclin-dependent protein kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine","volume":"243","author":"de","year":"1997","journal-title":"Eur J Biochem"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1074-5521(98)90170-3","article-title":"Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino acid substitution","volume":"5","author":"Eyers","year":"1998","journal-title":"Chem Biol"},{"key":"10.1016\/S1367-5931(99)80067-2_bib38","doi-asserted-by":"crossref","first-page":"15605","DOI":"10.1074\/jbc.273.25.15605","article-title":"Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP-binding pocket","volume":"273","author":"Gum","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0195","doi-asserted-by":"crossref","first-page":"28766","DOI":"10.1074\/jbc.273.44.28766","article-title":"Direct inhibition of cyclooxygenase-1 and-2 by the kinase inhibitors SB 203580 and PD 98059","volume":"273","author":"Borsch-Haubold","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80067-2_bib40","doi-asserted-by":"crossref","first-page":"30075","DOI":"10.1074\/jbc.272.48.30075","article-title":"Protein kinase C\u03b6 as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes","volume":"272","author":"Standaert","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80067-2_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-5793(96)01510-4","article-title":"The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase 1\u03b2 (Rsk-2) and p70 S6 kinase","volume":"402","author":"Alessi","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0210","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-5793(99)00552-9","article-title":"Use of a drug-resistant mutant of SAPK2a\/p38 to validate the in vivo specificity of SB 203580","volume":"451","author":"Eyers","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1016\/S1367-5931(99)80067-2_reference0215","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/9035","article-title":"Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases","volume":"1","author":"Hoessel","year":"1999","journal-title":"Nat Cell Biol"},{"key":"10.1016\/S1367-5931(99)80067-2_bib44","doi-asserted-by":"crossref","first-page":"13846","DOI":"10.1021\/bi980832y","article-title":"The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding","volume":"37","author":"Frantz","year":"1998","journal-title":"Biochemsitry"},{"key":"10.1016\/S1367-5931(99)80067-2_bib45","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/10533","article-title":"Blockade of the MAP kinase pathway suppresses growth of colon tumours in vivo","volume":"5","author":"Sebolt-Leopold","year":"1999","journal-title":"Nat Med"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593199800672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593199800672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:13:15Z","timestamp":1761271995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593199800672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,8]]}},"alternative-id":["S1367593199800672"],"URL":"https:\/\/doi.org\/10.1016\/s1367-5931(99)80067-2","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[1999,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The development and therapeutic potential of protein kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1367-5931(99)80067-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1999 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}